• Phase II study (N = 132)
• Adjuvant cisplatin/pemetrexed superior to cisplatin/vinorelbine in terms of treatment delivery (95.5% vs 75.4%) and dose-limiting hematologic toxicity (10% vs 74%)
• Conclusions regarding efficacy comparisons await larger, Phase III studies

Although adjuvant chemotherapy for NSCLC was introduced about a decade ago, in recent years few significant data sets have emerged to help advance this therapeutic approach. Interestingly, this has not stopped many lung cancer investigators and general oncologists from adapting their practice patterns by extrapolating data from the advanced-disease setting and regularly employing pemetrexed as part of their standard platinum-based adjuvant doublet. This small yet pragmatic study demonstrates that the thinking behind this practice — specifically that regimens with pemetrexed are generally better tolerated and more likely to be delivered than other adjuvant options — was sound, and while definitive efficacy data may not emerge from this study in the future, it does provide additional comfort and support for cisplatin/pemetrexed as a reasonable choice in the early disease setting.